Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19174157 | 0.87 | CYP4F2 (0.72) | CYP4F2CYP4A11PPARGPPARAMLNR | |
| SCHEMBL6846728 | 0.87 | CYP4F2 (0.72) | CYP4F2CYP4A11PPARGPPARAMLNR | |
| SCHEMBL14681244 | 0.87 | CYP4F2 (0.72) | CYP4F2CYP4A11PPARGPPARAMLNR | |
| SCHEMBL29397407 | 0.87 | CYP4F2 (0.72) | CYP4F2CYP4A11PPARGPPARAMLNR | |
| SCHEMBL908570 | 0.87 | CYP4F2 (0.72) | CYP4F2CYP4A11PPARGPPARAMLNR | |
| SCHEMBL2426350 | 0.83 | CYP4F2 (0.51) | CYP4F2CYP4A11PPARGPPARACHRM1 | |
| SCHEMBL2005546 | 0.80 | CYP4F2 (0.52) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL13762677 | 0.80 | CYP4F2 (0.52) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL29601366 | 0.80 | CYP4F2 (0.52) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL7229977 | 0.80 | CYP4F2 (0.52) | CYP4F2CYP4A11MLNRADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265596-B1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM SPA (IT) | 2016-06-01 | — | — | EP | disclosed |
| US-8981127-B2 | Method for preparing nebivolol | ZACH SYSTEM (FR) | 2015-03-17 | — | — | US | disclosed |
| US-8969597-B2 | Process for preparing nebivolol | ZACH SYSTEM S.P.A. (IT) | 2015-03-03 | — | — | US | disclosed |
| EP-2456768-B1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM SPA (IT) | 2014-11-19 | — | — | EP | disclosed |
| EP-2456768-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZaCh System S.p.A. (IT) | 2012-05-30 | — | — | EP | disclosed |
| US-20120108826-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM SPA (IT) | 2012-05-03 | — | — | US | disclosed |
| US-8084629-B2 | Process for preparing nebivolol | ZACH SYSTEM S.P.A. (IT) | 2011-12-27 | — | — | US | disclosed |
| US-20110237808-A1 | METHOD FOR PREPARING NEBIVOLOL | ZACH SYSTEM (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110021793-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2011-01-27 | — | — | US | disclosed |
| WO-2011009628-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM SPA (IT) | 2011-01-27 | — | — | WO | disclosed |
| EP-2265596-A2 | PROCESS FOR PREPARING NEBIVOLOL | ZaCh System S.p.A. (IT) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009121710-A2 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237808-A1 | METHOD FOR PREPARING NEBIVOLOL | ADRB1, ADRA1B, ADRB2 | CYP4F2 160/4885CYP4A11 13/4885PPARG 2701/4885 |
| US-20120108826-A1 | PROCESS FOR PREPARING NEBIVOLOL | ADRB1, ADRB2, ADRB3 | CYP4F2 33/4885CYP4A11 6/4885PPARG 1228/4885 |
| US-20110021793-A1 | PROCESS FOR PREPARING NEBIVOLOL | ADRB1, ADRA2B, ADRA1B | CYP4F2 176/4885CYP4A11 12/4885PPARG 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.